Heinz Lubenau

Heinz Lubenau

Company: NEC OncoImmunity

Job title: Chief Drug Development Officer


Immune Response & More – Oral Bacteria-Based DNA Vaccines for Individualized Neoantigen Targeting 2:30 pm

Targeting AI-predicted immunogenic neoantigens Monitoring immune-biomarkers potentially associated with clinical responses Combining with Checkpoint InhibitorsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.